Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,276 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07500831 | Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma | not yet recruiting | N/A | 43 | Qilu Hospital of Shandong UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07502027 | A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 4 | 55 | Huazhong University of Science and Technology |
| 0 |
| Mar 30, 2026 |
| clinicaltrials |
| NCT06396754 | Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC(AIDOBE) | not yet recruiting | — | 50 | Institute of Cancer Research, United KingdomOTHER | 0 | Mar 27, 2026 | clinicaltrials |
| NCT06418724 | Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma(NEOPECS) | not yet recruiting | Phase 2 | 27 | Melanoma and Skin Cancer Trials LimitedOTHER | 0 | Mar 27, 2026 | clinicaltrials |
| NCT07494435 | Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC | not yet recruiting | Phase 2 | 230 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07497958 | Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy | not yet recruiting | N/A | 174 | Sun Yat-sen UniversityOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07492043 | Breast Tumour Size Measurement by Field Cycling Imaging(BREVIA) | not yet recruiting | — | 12 | University of AberdeenOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07470840 | SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma | not yet recruiting | Phase 2 | 27 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07489768 | GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence Monitoring(CCGLC-019) | not yet recruiting | — | 162 | Tongji HospitalOTHER | 0 | Mar 24, 2026 | clinicaltrials |
| NCT07491783 | Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial | not yet recruiting | Phase 2 | 52 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07491822 | A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer | not yet recruiting | N/A | 43 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 24, 2026 | clinicaltrials |
| NCT07312370 | Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing | not yet recruiting | Phase 4 | 120 | LanZhou UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07466810 | Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology | not yet recruiting | N/A | 30 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07485920 | A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 4 | 20 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07486687 | Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy(PLANET) | not yet recruiting | Phase 3 | 1,000 | The Netherlands Cancer InstituteOTHER | 0 | Mar 20, 2026 | clinicaltrials |
| NCT06876038 | Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions | not yet recruiting | Phase 2 | 65 | University of Massachusetts, BostonOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07482774 | Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma(TME-ESCC) | not yet recruiting | — | 12 | Nanjing Medical UniversityOTHER | 0 | Mar 19, 2026 | clinicaltrials |
| NCT07481032 | Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study | not yet recruiting | N/A | 1,034 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Mar 18, 2026 | clinicaltrials |
| NCT07477418 | PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)(PRISM-TAMP) | not yet recruiting | Phase 1 / Phase 2 | 10 | University of VermontOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07478705 | Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging(EINSTEIN-TNBC) | not yet recruiting | N/A | 30 | Sunnybrook Health Sciences CentreOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT07001995 | Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07472647 | SYS6090 Combination Therapy in Advanced Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 596 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Mar 16, 2026 | clinicaltrials |
| NCT07469241 | Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.(FUTURE-3) | not yet recruiting | Phase 2 | 50 | Fudan UniversityOTHER | 0 | Mar 13, 2026 | clinicaltrials |
| NCT07470203 | Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer | not yet recruiting | — | 42 | Peking University Cancer Hospital & InstituteOTHER | 0 | Mar 13, 2026 | clinicaltrials |
| NCT07471009 | Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Squamous Cell Head and Neck Cancer (HNSCC) to Study Resistance Mechanisms Induced by Standard Therapy(SPAR) | not yet recruiting | — | 120 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07460206 | Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment(PRELUDE) | not yet recruiting | Phase 2 | 108 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 0 | Mar 10, 2026 | clinicaltrials |
| NCT07461675 | Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection | not yet recruiting | Phase 3 | 30 | University of Geneva, SwitzerlandOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07457099 | Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | — | 85 | Zhujiang HospitalOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07458204 | Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer(EPPIL) | not yet recruiting | Phase 2 | 760 | Institut Jean-GodinotOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07454668 | Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases | not yet recruiting | Phase 1 | 20 | Baptist Health South FloridaOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07455422 | A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer(Endeavor-2) | not yet recruiting | N/A | 266 | University Hospital, AntwerpOTHER | 7 | Mar 6, 2026 | clinicaltrials |
| NCT07449637 | Real-World Treatment Patterns and Survival Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma. | not yet recruiting | — | 200 | Sohag UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07450287 | CardioNETPOL National Registry of Carcinoid Heart Disease(CardioNETPOL) | not yet recruiting | — | 120 | National Institute of Cardiology, Warsaw, PolandOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07444840 | How Does Pre-operative Biliary Drainage in Pancreatic Adenocarcinoma Affect Surgical Outcomes in Pancreatic Cancer Surgery(PBDSOO) | not yet recruiting | — | 90 | East Lancashire Hospitals NHS TrustOTHER | 0 | Mar 3, 2026 | clinicaltrials |
| NCT07446335 | A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 578 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07243067 | Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer | not yet recruiting | — | 300 | Mayo ClinicOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07438418 | An Observational Study on Gastric Cancer in High-risk Individuals | not yet recruiting | — | 3,000 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07432087 | Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 246 | Yue He, MDOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT07432594 | Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer | not yet recruiting | Phase 2 | 82 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT07434180 | Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary(Lu-FAP CUP) | not yet recruiting | Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07428148 | Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 60 | NYU Langone HealthOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06958224 | Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers(ESCAT) | not yet recruiting | N/A | 360 | University Hospital, LilleOTHER | 0 | Feb 20, 2026 | clinicaltrials |
| NCT07423117 | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy | not yet recruiting | Phase 1 | 102 | IntoCell, IncINDUSTRY | 0 | Feb 20, 2026 | clinicaltrials |
| NCT07410767 | Advanced Endoscopic Resections for Rectal Neoplasms | not yet recruiting | — | 300 | Jagiellonian UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07417241 | SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study | not yet recruiting | Phase 2 | 100 | Peking University Cancer Hospital & InstituteOTHER | 0 | Feb 18, 2026 | clinicaltrials |
| NCT07361575 | Study Comparing the Quality of Colon Cleanliness With Prepackaged LRD (Low-residue Diet) vs. Guided (POG).(POG) | not yet recruiting | N/A | 230 | Clinique Paris-BercyOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07412054 | Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC(BLP-HCC) | not yet recruiting | Phase 2 | 234 | Fudan UniversityOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT07414433 | Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma(BLOOD-TACE-M) | not yet recruiting | — | 60 | University of BelgradeOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07414927 | A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy | not yet recruiting | Phase 1 / Phase 2 | 48 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 30, 2026source: clinicaltrials